ABCL News and Press, AbCellera Biologics Inc. From 11/02/23

AbCellera Biologics Inc. (ABCL) is expected to report $-0.14 for Q3 2023

Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL)...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 4:30 p.m. Greenwich Mean Time (8:30 a.m. Pacific Time). A live audio webcast of the presentation may be accessed through a l...

AbCellera (Nasdaq: ABCL) will announce its third quarter 2023 financial results on Thursday, November 2, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link...

AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023. “We have made signi...

2023-09-25 10:25:32 ET Summary AbCellera's Q2 2023 shows plummeting revenues to $10.1M alongside surging R&D expenses of $36.5M, questioning capital allocation efficacy. The company boasts strong liquidity with $795.6M in assets but faces market volatility due to fragmented ow...

2023-09-20 09:10:42 ET More on AbCellera Biologics Seeking Alpha’s Quant Rating on AbCellera Biologics AbCellera Biologics: Promising Platform, But Watch-And-Wait Approach Advised AbCellera, Incyte partner for antibody-based cancer drugs Why did AbCell...

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing multi-target collaboration with Regeneron (Nasdaq: REGN) to discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four. “Having successfully delivered on tw...

2023-09-20 07:47:47 ET More on Exscientia and AI drug discovery Seeking Alpha’s Quant Rating on Exscientia Exscientia Is Worth The AI-Driven Speculation Exscientia gains as enrollments begin for cancer trial AI to represent 11% of healthcare budgets in...

2023-09-13 10:25:54 ET More on AbCellera, Incyte, etc. AbCellera Biologics Inc. ( ABCL ) Q2 2023 Earnings Call Transcript AbCellera Biologics Inc. 2023 Q2 - Results - Earnings Call Presentation Incyte Corporation ( INCY ) Q2 2023 Earnings Call Transcript ...